We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
(+909%)
Cap. Flow
+$433M
Cap. Flow
% of AUM
91.18%
Top 10 Holdings %
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.86M |
| 2 |
Barings BDC
BBDC
|
+$6.33M |
| 3 |
Oxford Square Capital
OXSQ
|
+$5.45M |
| 4 |
ECC
Eagle Point Credit Company
ECC
|
+$5.29M |
| 5 |
FS KKR Capital
FSK
|
+$5.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$2.25M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$644K |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$605K |
| 4 |
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
|
+$603K |
| 5 |
uniQure
QURE
|
+$374K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.58% |
| 2 | Real Estate | 14.99% |
| 3 | Energy | 13.55% |
| 4 | Healthcare | 12.23% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDCO
176
DELISTED
Medicines Co
MDCO
| $837K | 0.18% |
+22,945
| New | +$749K |
|
177
Biogen
BIIB
$29.9B
| $832K | 0.18% |
3,556
+1,180
| +50% | +$272K |
|
178
Regeneron Pharmaceuticals
REGN
$68.8B
| $830K | 0.18% |
2,652
+581
| +28% | +$193K |
|
179
Theravance Biopharma
TBPH
$874M
| $829K | 0.17% |
50,751
+22,139
| +77% | +$449K |
|
|
SGEN
180
DELISTED
Seagen Inc. Common Stock
SGEN
| $818K | 0.17% |
+11,817
| New | +$828K |
|
181
Neurocrine Biosciences
NBIX
$17.7B
| $814K | 0.17% |
9,646
-1,025
| -10% | -$84.2K |
|
|
ICPT
182
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $810K | 0.17% |
10,180
+3,042
| +43% | +$272K |
|
183
United Therapeutics
UTHR
$26.3B
| $808K | 0.17% |
10,348
+3,264
| +46% | +$305K |
|
184
Puma Biotechnology
PBYI
$406M
| $803K | 0.17% |
63,142
+29,764
| +89% | +$685K |
|
185
Enanta Pharmaceuticals
ENTA
$372M
| $796K | 0.17% |
9,433
-1,201
| -11% | -$108K |
|
186
Omeros
OMER
$709M
| $784K | 0.17% |
+49,968
| New | +$897K |
|
187
Vanda Pharmaceuticals
VNDA
$312M
| $781K | 0.16% |
+55,444
| New | +$882K |
|
|
CELG
188
DELISTED
Celgene Corp
CELG
| $775K | 0.16% |
+8,388
| New | +$797K |
|
189
Franklin FTSE India ETF
FLIN
$2.69B
| $676K | 0.14% |
29,077
+586
| +2% | +$13.6K |
|
|
GTHX
190
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $440K | 0.09% |
14,360
+5,706
| +66% | +$120K |
|
|
PGNX
191
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $402K | 0.08% |
+65,214
| New | +$314K |
|
192
Krystal Biotech
KRYS
$9.88B
| $395K | 0.08% |
+9,800
| New | +$320K |
|
|
RARX
193
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $377K | 0.08% |
12,543
-3,645
| -23% | -$83.5K |
|
|
ARQL
194
DELISTED
Arqule Inc
ARQL
| $358K | 0.08% |
+32,522
| New | +$226K |
|
195
MeiraGTx Holdings
MGTX
$1.09B
| $349K | 0.07% |
+12,997
| New | +$268K |
|
196
Xencor
XNCR
$1.44B
| $348K | 0.07% |
8,514
+1,354
| +19% | +$44.5K |
|
197
Iovance Biotherapeutics
IOVA
$2.23B
| $342K | 0.07% |
+13,962
| New | +$210K |
|
|
TECX
198
Tectonic Therapeutic
TECX
$573M
| $320K | 0.07% |
1,641
+737
| +82% | +$159K |
|
|
APLS
199
DELISTED
Apellis Pharmaceuticals
APLS
| $319K | 0.07% |
12,600
-1,738
| -12% | -$35.4K |
|
200
TG Therapeutics
TGTX
$8.58B
| $318K | 0.07% |
36,741
-17,202
| -32% | -$130K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2019 Portfolio in Review
As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.
- Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
- Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
- Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
- Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
- Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
- Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.
Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.